摘要
抗HIV-1药物依非韦伦的血药浓度与不良反应和疗效密切相关。由于遗传、病理生理、合并用药等因素的影响,依非韦伦个体间血药浓度变异较大,导致部分使用标准剂量的患者出现病毒学失败或不良反应发生率增加的问题。本文综述依非韦伦个体化用药的必要性及其意义,治疗药物监测(TDM)及基因型指导下的个体化用药实践进展,归纳个体化用药的对象和时机,期望为优化国内HIV-1感染者依非韦伦的使用提供必要参考。
The plasma concentration of anti-HIV drug efavirenz is closely related to drug adverse reactions and efficacy. However, in some HIV-1 infected patients who were taken standard dose of efavirenz, their plasma concentration is varied greatly due to the difference of genetic and physio-pathological factor. It causes virological failure and increased incidence of adverse reactions. Many researchers point out that individualized medication is a good solution. This review describes the research progress on efavirenz individualized medication guided by genotype and therapeutic drug monitoring（TDM） for the reference to optimize the use of efavirenz in HIV-1 infected patients.
出处
《世界临床药物》
CAS
2014年第5期257-263,共7页
World Clinical Drug
基金
国家十二五重大新药创制--抗艾滋病病毒新药临床评价研究技术平台建设(2012ZX09303013)
